Skip to main content
Richardson D, Zhan L, Reynolds M, Hollis K, McRoy L, Mitra D, Mahtani R. Trends in daily mood, pain, and fatigue among participants in the MADELINE study. Poster presented at the 2019 San Antonio Breast Cancer Symposium; December 11, 2019. San Antonio, TX.
Kabadi SM, Goyal RK, Nagar SP, Davis KL, Le H, Du XL, Jain P, Wang ML, Romaguera JE, Kaye JA. Overall survival, adverse events, and economic burden in Medicare-insured patients with mantle cell lymphoma receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):63. doi: 10.1182/blood-2019-122841
Dawson KL, Price MA, Torney PA, Gonzalez V, Sae-Hau M, Weiss E, Mange B, Mansfield C, Comenencia-Ortiz E, Masaquel A, Ravelo A. Patient-reported disease burden and age: results from a national patient advocacy survey of patients with chronic lymphocytic leukemia, diffuse large-B-cell lymphoma and follicular lymphoma. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 9, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):4778. doi: 10.1182/blood-2019-123644
Garcia-Albeniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. Prospective biomarker study in advanced RAS wild‐type colorectal cancer: POSIBA Trial (GEMCAD 10‐02). Oncologist. 2019 Nov;24(11):e1115-22. doi: 10.1634/theoncologist.2018-0728
Price MA, Joish VN, Schwartz S, Fish-Steagall A, Bennett L, Darden C, Tesfaye E, Arnold K, Wason S, Lapuerta P. Xermelo patient registry: improvements in clinical outcomes, patients satisfaction, and weight with telotristat ethyl in the real-world. Poster presented at the 2019 North American Neuroendocrine Tumor Society (NANETS) Conference; October 3, 2019. Boston, MA.
Goyal RK, Cuyun Carter G, Nagar SP, Smyth EN, Price GL, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, survival, and economic outcomes in Medicare-enrolled, older patients with HR+/HER2– metastatic breast cancer. Curr Med Res Opin. 2019 Oct;35(10):1699-710. doi: 10.1080/03007995.2019.1615422
Shah R, Girard N, Nagar S, Griesinger F, Roeper J, Davis KL, Bakker NA, Thakrar B, Taylor A, Feliciano J. Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI). Poster presented at the ESMO 2019 Congress; September 27, 2019. Barcelona, Spain.
Mazieres J, Ahn MJ, Chouaid C, Kron A, Wolf J, Goyal RK, Davis KL, Perrinjaquet M, Pham T, Knoll S. Genetic testing patterns, treatment characteristics, and overall survival in ALK-positive metastatic NSCLC patients treated with Ceritinib. Poster presented at the 2019 World Conference on Lung Cancer; September 8, 2019. Barcelona, Spain.
Gutierrez L, Booth H, Dedman D, Crellin E, Kaye JA, Franzoni C, Arana A, Schmitt-Egenolf M, Sundstrom A, Bystrom C. Case validation of cutaneous lymphoma to minimize protopathic bias. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):645. doi: 10.1002/pds.4864
Jahn B, Todorovic J, Bundo M, Sroczynski G, Conrads-Frank A, Rochau U, Endel G, Wilbacher F, Malbaski N, Popper N, Chhatwal J, Greenberg D, Mauskopf J, Siebert U. Budget impact analysis of cancer screening: A methodological review. Appl Health Econ Health Policy. 2019 Aug;17(4):493-511. doi: 10.1007/s40258-019-00475-6
Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol. 2019 Aug;10(4):674-87. doi: 10.21037/jgo.2019.03.11
Harris D, Casso D, Midkiff K, Anderson A, Gilsenan A, Oliveria A, Andrews E, Kellier-Steele N. Methods, results, and lessons learned from two postmarketing drug safety surveillance studies linking state cancer registry data to large pharmacy databases. Presented at the 2019 NAACCR / IACR Combined Annual Conference; June 11, 2019. Vancouver, Canada.
Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Odom D, Gnanasakthy A, Suryanarayan K, Cain L, Romanus D, Rajkumar SV, Dimopoulos MA. Health-related quality of life (HRQOL) outcomes of oral ixazombi maintenance therapy post autologous stem cell transplant (ASCT) in newly diagnosed mulitple myeloma (NDMM) from TOURMALINE-MM3. Poster presented at the 24th Congress of the European Hematology Association; June 2019. Amsterdam, The Netherlands. [abstract] Hemasphere. 2019 Jun; 3:266-7.
Price M, Ravelo A, Sae-Hau M, Torney PA, Gonzalez V, Weiss ES, Mansfield C, Mange B, Comenencia Ortiz E, Masaquel A, Lamont Dawson K. Patient-reported disease burden in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma: results from a national patient advocacy survey. Poster presented at the 2019 ASCO Annual Meeting; May 2019. [abstract] J Clin Oncol. 2019 May 26; 37(15_suppl):e18198. doi: 10.1200/JCO.2019.37.15_suppl.e18198
Millar M, Kinney AY, Camp N, Cannon-Albright L, Hashibe M, Penson D, Kirchhoff A, Neklason D, Gilsenan A, Dieck GS, Stroup AM, Edwards SL, Bateman C, Carter ME, Sweeney C. Predictors of response outcomes for research recruitment through a central cancer registry: evidence from 17 population-based studies. Am J Epidemiol. 2019 May 1;188(5):928-39. doi: 10.1093/aje/kwz011
Horn L, Bauml J, Forde PM, Davis KL, Myall NJ, Sasane M, Dalal A, Culver K, Wozniak AJ, Baik CS, Mutebi A, Zhang P, Wakelee HA, Johnson BE. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. Lung Cancer. 2019 Feb;128(2019):74-90. doi: 10.1016/j.lungcan.2018.12.003